Lenacapavir Looks Promising for Once-Yearly PrEP

New research presented at CROI 2025 paves the way for Gilead Sciences to pursue Phase 3 testing of a highly-anticipated once-yearly formulation of long-acting injectable PrEP.

Thirteen of the nation’s leading LGBTQ+, HIV, and health organizations are uniting to raise the alarm about the Trump administration’s planned actions to defund HIV prevention at the CDC.

SFAF hosted the “Pre-CROI Community HIV Cure Research Workshop” to bring together people working towards an HIV cure with community members interested in learning more about novel strategies.

Clinicians, researchers, and scientists gathered alongside advocates and community members to protest the Trump administration's cuts to critical HIV funding and programs.

Nico Lang paints a vivid portrait of what it means to grow up, find joy, and make home in today’s America as a trans teen.

SFAF researchers Hyman Scott, MD, MPH, and Mike Barry, PhD, presented data from Magnet's Doxy PEP program at CROI 2025.

With disruptions to PEPFAR, USAID, and other federally-funded programs, there will be devastating loss of life, increased mother-to-child transmission, and millions of people losing access to care globally.

Research presented at CROI 2025 by San Francisco AIDS Foundation (SFAF) researchers sheds light into the Doxy PEP “continuum of care” experienced by clients at Magnet.